TD Cowen raised the firm’s price target on Gilead (GILD) to $145 from $125 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks
- Gilead price target raised to $145 from $140 at Truist
- Gilead price target raised to $156 from $140 at Citi
- Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- Gilead price target raised to $155 from $145 at UBS